Human Vaccines & Immunotherapeutics (Jan 2022)

Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues

  • Johnna Perdrizet,
  • Carlos Felipe S. Santana,
  • Thais Senna,
  • Rodrigo Fernandes Alexandre,
  • Rodrigo Sini de Almeida,
  • Julia Spinardi,
  • Matt Wasserman

DOI
https://doi.org/10.1080/21645515.2021.1917237
Journal volume & issue
Vol. 18, no. 1

Abstract

Read online

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.” Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.